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Antimycobacterial activityA B S T R A C T
During recent years, the implication of nanoparticles (NPs) as drug delivery systems has
gained much scientific attention. As drugs do not deliver themselves, a nanoparticle can
act by optimizing drug delivery in the right place, at the right time and at the right dosage.
In previous years, this research successfully developed and evaluated the ChPL-NPs
nanoparticles (chitosan protein–lipid) [US patent pending 20140370500]. In the present
investigation, rifampicin (RIF) ChPL-NPs nanoparticles were designed and developed.
Consequently, the in vitro release of RIF ChPL-NPs nanoparticles was investigated.
Material and methods: Briefly, chitosan powder (90 KD and 90% degree of deacetylation) was
dissolved (1% acetic-acid) andmixedwith gelatin (3%). Then, the lipid and rifampin in ether
was precipitated by rotary vacuum evaporator. Under high speed homogenizer
(12,000 rpm), both solutions (chitosan–gelatin & rifampin–lipid) were mixed [US patent
pending 20140370500]. The obtained RIF ChPL-NPs were put into a dialysis bag with
cut-off 14 KD in phosphate buffer solution (pH = 7.4). The release of RIF was obtained by
reverse phase HPLC using C18 (250 · 4.6 mm, 5 lm) column. The mobile phase consisted
of 50:50 v/v acetonitrile and 10 mm potassium dihydrogen phosphate (pH = 3.2) and flow
rate 1 ml/min. The column temp was maintained at 25 C with UV detection at 335 nm.
Results and conclusions: The average size of RIF ChPL-NPswasabout 50–250 nm.The release of
RIF from the dialysis bag started after 30 min whichwas 2400 ng/ml; after 16 h the release of
RIFwas15,000 ng/ml; andat 40 h the concentration reached to 19,600 ng/ml. Therefore, these
results showed a slow release of RIF from ChPL-NPs. Basically, the intensity of the surface
charges in nanoparticle is important as it determines their interaction with bioactive com-
pound. In RIF ChPL-NPs, lipid had negative charges, whereas chitosan and gelatin had posi-
tive charges. The electrostatic interaction between oppositely charged ionswould ultimately
cause an effective system drug delivery. RIF ChPL-NPs is not only suitable for intravenous
administration, but it can be used as an inhalation aerosol, because this nanoparticle has a
capacity to adhere to mucosal surfaces and transiently open the tight junction.
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